In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project ...

After several quarters on a steady sales roll as the world’s first treatment for metabolic dysfunction-associated ...

Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply ...

With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion ...

The CDC’s Advisory Committee on Immunization Practices (ACIP) will push out its February vaccine confab to an undetermined date next month, Bloomberg reported Thursday, citing an unnamed person close ...

Eli Lilly is partnering on Team USA’s push to help Olympic and Paralympic athletes hurdle the challenges of recovering from ...

Outside the drug’s current urticaria niche, Novartis is also developing remibrutinib in myasthenia gravis and multiple ...

In recent months, Johnson & Johnson has massively upped its spending on television advertisements for immunology heavyweight Tremfya, with the brand ...

In his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce ...

In the seven-plus years since Bayer closed its mammoth buyout of Monsanto, the combined company has struggled to contain ...

Some six years after the FDA approved Eli Lilly’s Retevmo to treat lung a | Six years after the FDA approved Eli Lilly’s ...

After winning an initial U.S. nod in July 2023, Beyfortus has gone on to do gangbusters for Sanofi and AZ, growing total sales 9.5% last year for a total haul of 1.78 billion euros (roughly $2.1 ...